JNJ analyst scorecard · Johnson & Johnson
55 rating actions on JNJ in the last 12 months. Of 71 price targets that resolved, 37 were reached while they stood, 34 were replaced by the same firm first, and 0 fell short at their deadline. Ratings: 71% Buy-type, 29% Hold-type, 0% Sell-type. Consensus target $279, 2% above the last close.
Checked through 2026-10-29 · last close $274.73 (2026-10-29). Rebuilt every morning.
What the Holds say: 16 Hold-type ratings on JNJ in the last 12 months carried a median target +2% from the price on the day; 38% sat below it.
Firm by firm
| Firm | Latest rating | Date | Latest target | Targets reached | Replaced early | Resolved | Ratings vs sector |
|---|---|---|---|---|---|---|---|
| Guggenheim | Buy | 2026-10-07 | $287 | 3 | 3 | 6 | 1 of 1 |
| Wells Fargo | Overweight | 2026-10-16 | $287 | 3 | 3 | 6 | 1 of 1 |
| RBC Capital | Outperform | 2026-10-14 | $280 | 4 | 9 | 13 | 1 of 1 |
| Morgan Stanley | Overweight | 2026-10-15 | $292 | 3 | 9 | 12 | — |
| Citigroup | Buy | 2026-10-05 | $303 | 1 | 7 | 8 | 1 of 1 |
| Leerink Partners | Outperform | 2026-10-14 | $272 | 2 | 1 | 3 | — |
| TD Cowen | Buy | 2026-07-13 | $300 | 1 | 0 | 1 | — |
| Raymond James | Outperform | 2026-07-16 | $265 | 4 | 0 | 4 | 1 of 1 |
| Scotiabank | Sector Outperform | 2026-01-22 | $265 | 1 | 0 | 1 | — |
| Goldman Sachs | Buy | 2025-12-19 | $240 | 3 | 0 | 3 | 1 of 1 |
| Barclays | Equal-Weight | 2026-04-15 | $255 | 3 | 0 | 3 | — |
| Bank of America | Neutral | 2026-07-10 | $263 | 4 | 1 | 5 | — |
| JPMorgan | Neutral | 2026-09-29 | $285 | 1 | 0 | 1 | — |
| HSBC | Buy | 2026-09-10 | $320 | 0 | 1 | 1 | — |
| Stifel | Hold | 2026-04-15 | $250 | 1 | 0 | 1 | — |
| UBS | Buy | 2026-09-02 | $320 | 2 | 0 | 2 | 1 of 1 |
| Freedom Capital Markets | Hold | 2026-01-27 | $220 | — | — | 0 | — |
| Freedom Broker | Hold | 2026-01-27 | $220 | — | — | 0 | — |
| Bernstein | Market Perform | 2026-01-09 | $208 | — | — | 0 | — |
Counts for one firm on one stock are small and move together; they are a record, not a grade. Neither the firms nor JNJ carry a letter here. Why →
Every call, last 12 months
| Date | Firm | Rating | Action | Price at call | Target | Target status | Move in the 30 days before |
|---|---|---|---|---|---|---|---|
| 2026-10-16 | Wells Fargo | Overweight | maintained | $255.56 | $287 | running to 2027-10-16 | -4.4% |
| 2026-10-15 | Morgan Stanley | Overweight | maintained | $253.28 | $292 | running to 2028-04-15 | -5.2% |
| 2026-10-14 | Leerink Partners | Outperform | maintained | $253.91 | $272 | reached 2026-10-29 | -4.7% |
| 2026-10-14 | Wells Fargo | Overweight | maintained | $253.91 | $275 | replaced 2026-10-16, new $287 | -4.7% |
| 2026-10-14 | RBC Capital | Outperform | maintained | $253.91 | $280 | running to 2027-10-14 | -4.7% |
| 2026-10-07 | Guggenheim | Buy | reiterated | $258.45 | $287 | running to 2027-10-07 | -6.1% |
| 2026-10-06 | RBC Capital | Outperform | maintained | $254.78 | $290 | replaced 2026-10-14, new $280 | -7.4% |
| 2026-10-05 | Citigroup | Buy | maintained | $252.93 | $303 | running to 2027-10-05 | -8.1% |
| 2026-09-29 | JPMorgan | Neutral | maintained | $267.57 | $285 | running to 2027-09-29 | -0.2% |
| 2026-09-10 | HSBC | Buy | maintained | $266.35 | $320 | running to 2027-09-10 | +2.5% |
| 2026-09-02 | UBS | Buy | maintained | $275.21 | $320 | running to 2027-09-02 | +8.2% |
| 2026-08-06 | Guggenheim | Buy | maintained | $256.98 | $287 | running to 2027-08-06 | -3.8% |
| 2026-08-03 | Wells Fargo | Overweight | maintained | $254.41 | $282 | replaced 2026-10-14, new $275 | -3.3% |
| 2026-07-17 | Guggenheim | Buy | reiterated | $253.04 | $270 | replaced 2026-08-06, new $287 | +8.0% |
| 2026-07-16 | Raymond James | Outperform | maintained | $249.97 | $265 | reached 2026-07-27 | +6.3% |
| 2026-07-16 | RBC Capital | Outperform | reiterated | $249.97 | $287 | replaced 2026-10-06, new $290 | +6.3% |
| 2026-07-16 | Wells Fargo | Overweight | maintained | $249.97 | $272 | replaced 2026-08-03, new $282 | +6.3% |
| 2026-07-16 | Morgan Stanley | Overweight | maintained | $249.97 | $294 | replaced 2026-10-15, new $292 | +6.3% |
| 2026-07-13 | TD Cowen | Buy | maintained | $257.77 | $300 | running to 2027-07-13 | +7.0% |
| 2026-07-13 | RBC Capital | Outperform | maintained | $257.77 | $287 | replaced 2026-10-06, new $290 | +7.0% |
| 2026-07-10 | Bank of America | Neutral | maintained | $256.98 | $263 | within 5% of price when set | +7.8% |
| 2026-07-08 | Morgan Stanley | Overweight | maintained | $263.40 | $284 | replaced 2026-07-16, new $294 | +13.5% |
| 2026-07-08 | Citigroup | Buy | maintained | $263.40 | $298 | replaced 2026-10-05, new $303 | +13.5% |
| 2026-06-26 | Guggenheim | Buy | maintained | $254.66 | $270 | replaced 2026-08-06, new $287 | +10.1% |
| 2026-05-13 | Leerink Partners | Market Perform → Outperform | upgrade | $230.42 | $265 | reached 2026-07-07 | -3.2% |
| 2026-04-15 | Barclays | Equal-Weight | maintained | $238.67 | $255 | reached 2026-06-29 | -1.9% |
| 2026-04-15 | Stifel | Hold | maintained | $238.67 | $250 | within 5% of price when set | -1.9% |
| 2026-04-15 | Wells Fargo | Overweight | maintained | $238.67 | $263 | reached 2026-07-02 | -1.9% |
| 2026-04-10 | Morgan Stanley | Overweight | maintained | $238.46 | $267 | reached 2026-07-07 | -1.9% |
| 2026-03-30 | RBC Capital | Outperform | reiterated | $242.49 | $255 | reached 2026-06-29 | -2.4% |
| 2026-03-19 | Barclays | Equal-Weight | maintained | $237.60 | $234 | within 5% of price when set | -2.4% |
| 2026-03-17 | HSBC | Buy | maintained | $238.11 | $280 | replaced 2026-09-10, new $320 | -2.2% |
| 2026-03-11 | Citigroup | Buy | maintained | $242.99 | $274 | replaced 2026-07-08, new $298 | +1.8% |
| 2026-03-05 | JPMorgan | Neutral | maintained | $239.63 | $250 | within 5% of price when set | +2.8% |
| 2026-02-03 | RBC Capital | Outperform | maintained | $233.10 | $255 | reached 2026-06-29 | +12.4% |
| 2026-01-28 | Morgan Stanley | Equal-Weight → Overweight | upgrade | $227.72 | $262 | replaced 2026-04-10, new $267 | +9.7% |
| 2026-01-27 | Freedom Capital Markets | Hold | maintained | $224.44 | $220 | within 5% of price when set | +8.1% |
| 2026-01-27 | Freedom Broker | Hold | maintained | $224.44 | $220 | within 5% of price when set | +8.1% |
| 2026-01-23 | Guggenheim | Buy | maintained | $220.14 | $240 | reached 2026-02-11 | +6.0% |
| 2026-01-22 | Citigroup | Buy | maintained | $218.49 | $250 | replaced 2026-03-11, new $274 | +6.2% |
| 2026-01-22 | Bank of America | Neutral | maintained | $218.49 | $221 | within 5% of price when set | +6.2% |
| 2026-01-22 | TD Cowen | Buy | maintained | $218.49 | $250 | reached 2026-06-26 | +6.2% |
| 2026-01-22 | Morgan Stanley | Equal-Weight | maintained | $218.49 | $200 | replaced 2026-01-28, new $262 | +6.2% |
| 2026-01-22 | Wells Fargo | Overweight | maintained | $218.49 | $240 | reached 2026-02-11 | +6.2% |
| 2026-01-22 | Scotiabank | Sector Outperform | maintained | $218.49 | $265 | reached 2026-07-07 | +6.2% |
| 2026-01-22 | Stifel | Hold | maintained | $218.49 | $220 | within 5% of price when set | +6.2% |
| 2026-01-09 | Bernstein | Market Perform | maintained | $204.39 | $208 | within 5% of price when set | -1.0% |
| 2025-12-30 | Barclays | Equal-Weight | maintained | $206.91 | $217 | within 5% of price when set | -0.0% |
| 2025-12-19 | Goldman Sachs | Buy | maintained | $206.37 | $240 | reached 2026-02-11 | +1.9% |
| 2025-12-15 | Bank of America | Neutral | maintained | $214.17 | $220 | within 5% of price when set | +9.3% |
| 2025-12-12 | Morgan Stanley | Equal-Weight | maintained | $211.58 | $197 | replaced 2026-01-22, new $200 | +8.8% |
| 2025-12-11 | Citigroup | Buy | maintained | $210.01 | $232 | replaced 2026-01-22, new $250 | +8.3% |
| 2025-12-11 | RBC Capital | Outperform | maintained | $210.01 | $230 | reached 2026-02-02 | +8.3% |
| 2025-12-05 | Guggenheim | Buy | maintained | $201.93 | $227 | replaced 2026-01-23, new $240 | +8.6% |
| 2025-12-02 | Barclays | Equal-Weight | maintained | $205.42 | $197 | within 5% of price when set | +8.8% |
Also in Pharma
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How calls are checked
Every call is checked on the firm's own terms. A price target is followed until its own deadline (12 months unless the firm publishes a different horizon) and ends as reached (the stock closed at or beyond it while it stood), replaced (the same firm set a new target first) or short at deadline. A rating is compared with the stock's sector SPDR ETF on total return over the rating's life, because most big-firm ratings are relative: Overweight means "beat its peers", not "go up". Hold-type ratings are tracked, not graded. A firm is numbered only with 30+ resolved targets, and a letter prints only for a firm's whole record where an exact test separates it from a coin flip. None of this is a verdict on anyone's skill, and one day is never a grade. The full method →
Get the daily brief
Our take, the S&P 500 Pulse, the Street's calls and today's docket — one email, weekdays, 9 AM ET, 30 minutes before the open.